Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2000

01-12-2001 | Paper Report

H-chain CDR3 contribution in specificity of autoantibodies

Author: Fanny Monneaux

Published in: Arthritis Research & Therapy | Issue 1/2000

Login to get access

Excerpt

Systemic lupus erythematosus is characterized by the production of antibodies directed against various nuclear antigens. Many groups have focused on the sequence of the V region genes of antinuclear antibodies and several features accounting for DNA binding have emerged from these sequences, especially in VH-CDR (H3). In this study, the authors exchanged H3 domains between the 3H9 antibody and two donor antibodies, LG8-1 (closely related to 3H9) and ASWA1 (divergent from 3H9). The H3 domain of these three antibodies differed in the number of arginine residues and in overall charge and these antibodies share different specificities. Variant H chains were expressed together with the 3H9 light chain as single-chain Fv (scFv), and the five antibodies were then tested for their ability to bind nucleosomes, DNA and cardiolipin. …
Literature
1.
go back to reference Seal SN, Monestier M, Radic MZ: Diverse roles for the third complementarity determining region of the heavy chain (H3) in the binding of immunoglobulin Fv fragments to DNA, nucleosomes and cardiolipin. Eur J Immunol. 2001, 30: 3432-3440.CrossRef Seal SN, Monestier M, Radic MZ: Diverse roles for the third complementarity determining region of the heavy chain (H3) in the binding of immunoglobulin Fv fragments to DNA, nucleosomes and cardiolipin. Eur J Immunol. 2001, 30: 3432-3440.CrossRef
Metadata
Title
H-chain CDR3 contribution in specificity of autoantibodies
Author
Fanny Monneaux
Publication date
01-12-2001
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2000
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar-2001-66875

Other articles of this Issue 1/2000

Arthritis Research & Therapy 1/2000 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine